SEARCH:   Advanced

Blood, 1 November 2004, Vol. 104, No. 9, pp. 2933-2935. Prepublished online as a Blood First Edition Paper on July 6, 2004; DOI 10.1182/blood-2004-03-1209. This Article Full Text Full Text (PDF) All Versions of this Article: 2004-03-1209v1 104/9/2933    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Barrans, S. L. Articles by Jack, A. S. Search for Related Content PubMed PubMed Citation Articles by Barrans, S. L. Articles by Jack, A. S. Related Collections Neoplasia Gene Expression Brief Reports Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief report Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome Sharon L. Barrans, James A. L. Fenton, Alison Banham, Roger G. Owen, and Andrew S. Jack From Haematological Malignancy Diagnostic Service (HMDS), Academic Unit of Haematology and Oncology, Leeds General Infirmary, United Kingdom; and the LRF Immunodiagnostics Unit, Nuffield Department of Clinical Laboratory Sciences, University of Oxford, John Radcliffe Hospital, United Kingdom. FOXP1 (Forkhead box-P1) is a winged-helix transcription factor that is differentially expressed in resting and activated B cells. FOXP1 expression has been demonstrated in a subset of diffuse large B-cell lymphomas (DLBCLs) and is more common in the nongerminal center (non-GC), activated B-cell type; however, its prognostic significance is uncertain. We analyzed presentation lymph nodes from 126 patients with nodal DLBCL, previously classified according to GC and BCL2 status, for FOXP1 protein expression using standard immunocytochemistry. Uniform high FOXP1 expression was demonstrated in 23 of 126 patients with DLBCL. This high level of expression was almost exclusively confined to patients who lacked the GC phenotype, who expressed MUM-1 and BCL2 in the absence of t(14; 18), and who were identified as a subgroup of patients with particularly poor outcomes in a group with already poor prognoses. The data presented suggest that high FOXP1 expression is an independent prognostic factor in DLBCL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: H Adams, A Tzankov, A Lugli, and I Zlobec New time-dependent approach to analyse the prognostic significance of immunohistochemical biomarkers in colon cancer and diffuse large B-cell lymphoma J. Clin. Pathol., November 1, 2009; 62(11): 986 - 997. [Abstract] [Full Text] [PDF] A. Chadburn, A. Chiu, J. Y. Lee, X. Chen, E. Hyjek, A. H. Banham, A. Noy, L. D. Kaplan, J. A. Sparano, K. Bhatia, et al. Immunophenotypic Analysis of AIDS-Related Diffuse Large B-Cell Lymphoma and Clinical Implications in Patients From AIDS Malignancies Consortium Clinical Trials 010 and 034 J. Clin. Oncol., October 20, 2009; 27(30): 5039 - 5048. [Abstract] [Full Text] [PDF] W. W.L. Choi, D. D. Weisenburger, T. C. Greiner, M. A. Piris, A. H. Banham, J. Delabie, R. M. Braziel, H. Geng, J. Iqbal, G. Lenz, et al. A New Immunostain Algorithm Classifies Diffuse Large B-Cell Lymphoma into Molecular Subtypes with High Accuracy Clin. Cancer Res., September 1, 2009; 15(17): 5494 - 5502. [Abstract] [Full Text] [PDF] D de Jong, W Xie, A Rosenwald, M Chhanabhai, P Gaulard, W Klapper, A Lee, B Sander, C Thorns, E Campo, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium) J. Clin. Pathol., February 1, 2009; 62(2): 128 - 138. [Abstract] [Full Text] [PDF] G. M. Mead, S. L. Barrans, W. Qian, J. Walewski, J. A. Radford, M. Wolf, S. M. Clawson, S. P. Stenning, C. L. Yule, A. S. Jack, et al. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial) Blood, September 15, 2008; 112(6): 2248 - 2260. [Abstract] [Full Text] [PDF] S. Nakamura, H. Ye, C. M. Bacon, A. Goatly, H. Liu, L. Kerr, A. H. Banham, B. Streubel, T. Yao, M. Tsuneyoshi, et al. Translocations Involving the Immunoglobulin Heavy Chain Gene Locus Predict Better Survival in Gastric Diffuse Large B-Cell Lymphoma Clin. Cancer Res., May 15, 2008; 14(10): 3002 - 3010. [Abstract] [Full Text] [PDF] Lulu Fu, J. E. Girling, and P. A. W. Rogers Expression of Fox Head Protein 1 in Human Eutopic Endometrium and Endometriosis Reproductive Sciences, March 1, 2008; 15(3): 243 - 252. [Abstract] [PDF] P. J. Brown, S. L. Ashe, E. Leich, C. Burek, S. Barrans, J. A. Fenton, A. S. Jack, K. Pulford, A. Rosenwald, and A. H. Banham Potentially oncogenic B-cell activation-induced smaller isoforms of FOXP1 are highly expressed in the activated B cell-like subtype of DLBCL Blood, March 1, 2008; 111(5): 2816 - 2824. [Abstract] [Full Text] [PDF] R. Thomas, S. E. Duke, S. K. Bloom, T. E. Breen, A. C. Young, E. Feiste, E. L. Seiser, P.-C. Tsai, C. F. Langford, P. Ellis, et al. A Cytogenetically Characterized, Genome-Anchored 10-Mb BAC Set and CGH Array for the Domestic Dog J. Hered., August 16, 2007; (2007) esm053v1. [Abstract] [Full Text] [PDF] S. L. Barrans, J. A.L. Fenton, R. Ventura, A. Smith, A. H. Banham, and A. S. Jack Deregulated over expression of FOXP1 protein in diffuse large B-cell lymphoma does not occur as a result of gene rearrangement Haematologica, June 1, 2007; 92(6): 863 - 864. [Abstract] [Full Text] [PDF] N. J. Senff, J. J. Hoefnagel, P. M. Jansen, M. H. Vermeer, J. van Baarlen, W. A. Blokx, M. R. Canninga-van Dijk, M.-L. Geerts, K. M. Hebeda, P. M. Kluin, et al. Reclassification of 300 Primary Cutaneous B-Cell Lymphomas According to the New WHO-EORTC Classification for Cutaneous Lymphomas: Comparison With Previous Classifications and Identification of Prognostic Markers J. Clin. Oncol., April 20, 2007; 25(12): 1581 - 1587. [Abstract] [Full Text] [PDF] J. L. Rubenstein, J. Fridlyand, L. Abrey, A. Shen, J. Karch, E. Wang, S. Issa, L. Damon, M. Prados, M. McDermott, et al. Phase I Study of Intraventricular Administration of Rituximab in Patients With Recurrent CNS and Intraocular Lymphoma J. Clin. Oncol., April 10, 2007; 25(11): 1350 - 1356. [Abstract] [Full Text] [PDF] D. de Jong, A. Rosenwald, M. Chhanabhai, P. Gaulard, W. Klapper, A. Lee, B. Sander, C. Thorns, E. Campo, T. Molina, et al. Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications--A Study From the Lunenburg Lymphoma Biomarker Consortium J. Clin. Oncol., March 1, 2007; 25(7): 805 - 812. [Abstract] [Full Text] [PDF] X. Sagaert, P. de Paepe, L. Libbrecht, V. Vanhentenrijk, G. Verhoef, J. Thomas, I. Wlodarska, and C. De Wolf-Peeters Forkhead Box Protein P1 Expression in Mucosa-Associated Lymphoid Tissue Lymphomas Predicts Poor Prognosis and Transformation to Diffuse Large B-Cell Lymphoma J. Clin. Oncol., June 1, 2006; 24(16): 2490 - 2497. [Abstract] [Full Text] [PDF] I. S. Lossos and D. Morgensztern Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma J. Clin. Oncol., February 20, 2006; 24(6): 995 - 1007. [Abstract] [Full Text] [PDF] K. Kodama, C. Massone, A. Chott, D. Metze, H. Kerl, and L. Cerroni Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients Blood, October 1, 2005; 106(7): 2491 - 2497. [Abstract] [Full Text] [PDF] P. Farinha and R. D. Gascoyne Molecular Pathogenesis of Mucosa-Associated Lymphoid Tissue Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6370 - 6378. [Abstract] [Full Text] [PDF] E. Bettelli, M. Dastrange, and M. Oukka Foxp3 interacts with nuclear factor of activated T cells and NF-{kappa}B to repress cytokine gene expression and effector functions of T helper cells PNAS, April 5, 2005; 102(14): 5138 - 5143. [Abstract] [Full Text] [PDF] A. H. Banham, J. M. Connors, P. J. Brown, J. L. Cordell, G. Ott, G. Sreenivasan, P. Farinha, D. E. Horsman, and R. D. Gascoyne Expression of the FOXP1 Transcription Factor Is Strongly Associated with Inferior Survival in Patients with Diffuse Large B-Cell Lymphoma Clin. Cancer Res., February 1, 2005; 11(3): 1065 - 1072. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020